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Blood–brain barrier shuttle peptides: an emerging
paradigm for brain delivery
Benjamı´ Oller-Salvia,a Macarena Sa´nchez-Navarro,a Ernest Giraltab and
Meritxell Teixido´a
Brain delivery is one of the major challenges in drug development because of the high number of
patients suﬀering from neural diseases and the low eﬃciency of the treatments available. Although the
blood–brain barrier (BBB) prevents most drugs from reaching their targets, molecular vectors – known as
BBB shuttles – offer great promise to safely overcome this formidable obstacle. In recent years, peptide
shuttles have received growing attention because of their lower cost, reduced immunogenicity, and higher
chemical versatility than traditional Trojan horse antibodies and other proteins.
1. Introduction
Delivery to the brain is a major challenge in drug development
because an ageing population and the growing prevalence
of brain cancers are increasing the incidence of central nervous
system (CNS) diseases.1 Moreover, the lack of eﬃcient treat-
ments generates high direct and indirect costs, which together
correspond to 1/4th of the burden of all diseases in Europe and
high-income countries.2 Therefore, improving CNS drugs
would not only enhance the well-being of many people but also
considerably reduce health costs. However, a formidable obstacle
must be overcome to enable active compounds to reach their
targets in therapeutically relevant amounts: the blood–brain
barrier (BBB).3
Although many strategies to circumvent the BBB have been
proposed, to date none has shown a satisfactory eﬃciency–safety
balance. At one end of the spectrum, direct drug admini-
stration into the brain has a high risk and is very local and,
at the other end, the modification of molecules to enhance
their diffusion through the barrier is applicable only for some
small drugs. Among the non-invasive approaches, molecular
vectors – also known as BBB shuttles – (Fig. 1) have proved their
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potential in preclinical research over the last two decades,
and some of these compounds are in clinical trials. The BBB
shuttle4 concept includes Trojan horse antibodies5 and any other
molecule capable of transporting a cargo into the brain parench-
yma without affecting the BBB integrity. Over the last five years,
research into peptide shuttles has thrived because they over-
come some of the weaknesses of classical protein shuttles,
including complex derivatization and characterization, high
immunogenicity, and costly production. Of note, here we will
use the word peptide to refer to small proteins (with or without
structure) containing up to 50 amino acid residues.
In this review, crossing the BBB is presented as a tremendous
challenge but also as an excellent opportunity for drug delivery
into the brain. We first provide an overview of BBB shuttle
Fig. 1 BBB-shuttle mediated transport across the BBB. The BBB is formed mainly by the tight brain endothelium, which is surrounded by the basal
lamina and regulated by the other cells in the neurovascular unit, including pericytes, glial cells and neurons.6 BBB shuttles mediate drug delivery across
this barrier by taking advantage of endogenous transport pathways. Small molecules and peptides can be delivered using shuttles that undergo passive
diﬀusion and carrier-mediated transport. However, passive diﬀusion is altered by the physicochemical characteristics of the cargo, including logP, pKa,
molecular weight, topological polar surface area and hydrogen bonding.186 Carrier proteins usually undergo precise rearrangements to translocate
constructs into the cystosol,9 thus they are also highly sensitive to the modification of substrate properties. Conversely, adsorptive- or receptor-mediated
transcytosis allow the transport of a wider variety of cargoes, including proteins, viruses and nanocarriers. Despite the high eﬃciency of the former
mechanism in mediating tissue uptake, the latter has focussed most attention on brain delivery due to its potential targeting capacity.
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peptides and subsequently present the most advanced ones,
which are included in drug formulations that have reached
clinical trials. Then, the focus is given to three representative
case studies to illustrate some of the main achievements of
shuttle transport of diverse cargoes. Additionally, some strategies
that rescue unspecific shuttles are reported and the relevance of
protease-resistance is highlighted. Finally, we point out the main
trends in the field and the challenges to be addressed.
2. Toward minimized brain delivery
vectors
2.1. The blood–brain barrier
The BBB is a physical, metabolic and transport barrier that
tightly controls the transfer of substances from blood to neural
tissues and vice versa, thereby contributing to brain home-
ostasis.6–8 Endothelial cells on brain capillary walls are the
main constituents of this barrier and they form tight junctions
that hinder paracellular passage. Additionally, these cells have
many cytosolic and extracellular-membrane enzymes, down-
regulated vesicular transport and efflux pumps. The perme-
ability of the brain endothelium is influenced by the other cells
belonging to the neurovascular unit (Fig. 1) and is affected by
most CNS pathologies; however, BBB dysfunction is usually
only significant in advanced stages of disease and in the most
affected sites.
Despite its eﬃcient role as a barrier, the BBB is the main
gateway to the brain as it grants access to necessary ions,
nutrients and hormones – the maximal cell-capillary distance
is 20 mm, which can be permeated by small molecules in half a
second.9 Therefore, taking advantage of the endogenous trans-
port mechanisms present on the BBB is potentially the most
efficient way to deliver substances to any part of the brain.6 Many
small hydrophobic compounds (o500 Da) diffuse across the
endothelium membrane, while polar molecules such as glucose,
amino acids, and several peptides have specific carriers; these
highly selective transporters mediate transport into the endo-
thelium cytosol and from there to the brain extracellular space.
Indeed, even some macromolecules and also certain peptides
cross the BBB through endocytic mechanisms involving receptor-
mediated transcytosis (RMT) and/or adsorptive-mediated trans-
cytosis (AMT). In the process of transcytosis, the vesicle formed
circulates across the cell, bypassing the degradation pathway, and
eventually releases its content into the parenchyma by exocytosis.
AMT is considered non-specific and comprises all vesicular
transport mechanisms that do not involve protein receptors;
in AMT, endocytosis is generally promoted by the interaction of
the often positively charged molecule with membrane phospho-
lipids and the glycocalyx.
2.2. Brain delivery approaches
Nowadays most strategies for drug delivery into the brain that
circumvents the BBB are invasive,10 involving the highest risk of
brain damage or infection and requiring demanding set-ups.11,12
In addition, administration is often excessively localized and
diﬀusion in the brain is very limited, especially for large
molecules.13 Although alternative routes such as nasal delivery
are under investigation, most attention is focused on achieving
eﬃcient distribution of the drug through the extensive brain
vasculature.
Temporal disruption of the tight junctions of brain endo-
thelium by chemical or physical stimuli entails toxicity and the
risk of neuronal dysfunction.14 Hence, much eﬀort has been
channelled into improving transport across endothelial cells.
The most common strategies rely on enhancing lipophilicity
and positive charge, in order to increase passive diﬀusion and
mediate interaction with the anionic glycocalyx, respectively.
However, these modifications lead to higher unspecific uptake
inmany tissues often resulting in oﬀ-target eﬀects and, in addition,
they enhance recognition by eﬄux pumps.12,15 Amore selective way
to boost the permeation of certain small molecules into the
brain is to modify them by mimicking endogenous substrates
of BBB carriers.16 However, all these approaches require a high
degree of tailoring and are rarely applicable to large drugs such
as biotherapeutics.
A more general approach for drug delivery to the CNS
focuses on delivery vectors. Although biological vectors such
as viruses17,18 and modified cells19 have been used to increase
BBB transport, their safety, permeability across an intact barrier,
and brain selectivity are still limited.18–20 Conversely, molecular
vectors, dubbed BBB shuttles,4,21–33 aim to provide broadly applic-
able, selective and safer delivery systems.
2.3. BBB shuttle peptides
BBB shuttles allow the transport of a wide range of cargoes,
comprising small molecules, proteins, nanoparticles and genetic
material across the BBB. Substrates of natural carriers such as
glucose and neutral amino acids have been applied to transport
small molecules through their natural carriers on the BBB, while
for nanoparticles and biomolecules the focus has been set on
receptor ligand proteins since vesicular mechanisms tolerate a
wide range of cargo sizes.3 Remarkably, peptides have bridged
the gap between these two worlds.
The BBB shuttle concept was conceived byWilliamM. Pardridge
in the mid-1980s,34 inspired by chimeric proteins targeting cell
receptors. The first successful attempts relied first on cationized
albumin,35 which lacked brain selectivity, and then on IgGs directed
against insulin and transferrin receptors.36 However, the success of
these initial antibodies was limited by their high aﬃnity, which
hampered an eﬃcient release into the brain parenchyma.15,37
Therefore, a variety of protein shuttles have been investigated;
most of them are ligands of receptors on the brain endothelium
and include the following: apolipoproteins (Apo) A and E,38
receptor-associated protein (RAP),39 transferrin (Tf),40 lacto-
transferrin,41melanotransferrin (p97),42 and leptin.43 However, these
proteins compete with their endogenous counterparts. Although a
few non-endogenous proteins, such as wheat germ agglutinin44 and
a non-toxic mutant of diphtheria toxin (CRM197),45 have been
used, they also have shown moderate eﬃcacy and selectivity.
In recent years, research on antibodies has been relaunched
focussing on lower-aﬃnity IgG derivatives.21,37,46,47
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Despite the relative success of antibodies and other large
proteins, their production is expensive and high immuno-
genicity is an issue. This is why research in this field in the
last decade has focussed to a great extent on peptides. These
molecules combine the low cost of small drugs with the high
specificity of biologics.37,48 Peptides are easier to obtain and
characterize than the latter and have very low immunogenicity,
especially those without a rigid structure.49 Moreover, they dis-
play medium to low aﬃnities, a property that has been critical to
the development of anti-TfR shuttles.37 In addition, peptides are
amenable to chemical synthesis. This feature opens up the
possibility of applying a wide range of non-natural modifications
and of introducing a plethora of functional groups for site-
specific conjugation to proteins and nanocarriers. Furthermore,
reduced functional alteration of the cargo and enhanced shelf-
life are also important advantages over most proteins. Although
peptides have often been undervalued in pharmaceutical chem-
istry because of their low resistance to proteolytic degradation, this
limitation can now be overcome by means of various strategies
that will be described in section 7.50
Although some peptides had long been shown to cross the
BBB,51 the field of peptide shuttles was pioneered in 1999
by Stephen Dowdy and coworkers.52 In this seminal paper, the
authors demonstrated the capacity of a fragment from the HIV
TAT protein to deliver b-galactosidase into the brain and other
organs. However, it was in 2007 with RVG2953 that a peptide was
proven capable of transporting cargoes into the brain in a
selective fashion. Soon after, the great potential of Angiopep-254
and glutathione (GSH)55,56 as BBB shuttles was unravelled –
formulations including these peptides are currently in clinical
trials. Remarkably, in the last 5 years over 30 BBB shuttle
peptides with increasing efficiency and versatility have been
reported (Table 1).
3. Aiming for selectivity
The discovery of TAT peptide as a brain delivery vector, directed
initial research eﬀorts into finding BBB shuttles with high per-
meability across cell membranes. Passive diﬀusion and AMT
provide the highest transport since the first is considered
unsaturable and saturation concentrations for AMT are 3 orders
of magnitude higher than for RMT.57 Nevertheless, the need for
safer therapeutics has pushed research towards targeted strategies
in an attempt to achieve Paul Ehrlich’s ‘‘magic bullet’’.
3.1. Unspecific uptake
BBB shuttle peptides capable of increasing the brain uptake
of large cargoes in a non-selective way belong mainly to the
cell-penetrating peptide (CPP) family. CPPs comprise short
amphipathic and/or cationic sequences with a high capacity
to cross cell membranes without the need of a receptor.58,59
Most peptides with this property have been derived from protein
transduction domains (e.g. TAT60 and penetratin61), by hybridizing
these domains with antibiotic peptides (e.g. SynB162,63 and trans-
portan64), or through biomimetic design (e.g. oligoarginine65).
Although CPPs can enter cells through diﬀerent mechanisms,
when linked to large cargoes they mostly undergo endocytosis.
Therefore, it is generally assumed that they undergo AMT
across the BBB.57 However, exocytosis of the entire BBB shuttle
constructs from the endothelium is more controversial than in
RMT and they may accumulate in the endothelium as has been
reported for positively charged proteins such as lectins.44 By
contrast, a recent study using CPPs of four diﬀerent classes
suggests that trapping in brain capillaries of peptides alone
may be relatively low but indicates that brain parenchymal
accumulation does not correlate with their cell internalization
capacity.66
For small drugs (o300 Da), peptide shuttles formed by
2–4 amino acid residues that cross the BBB through passive
diffusion are more attractive since they may minimize the loss
of activity upon conjugation. In peptides diffusing across the
BBB, hydrogen bonding and water desolvation have a better
correlation with permeability than log P.67 Based on this
criterion, three families of BBB shuttle peptides, namely diketo-
piperazines,32 N-methylphenylalanines29–31 and phenylprolines,68
have been developed.
3.2. Targeting transporters
Most BBB shuttle peptides that interact with transporters have
been obtained from either neurotropic biomolecules or phage
display biopanning (Fig. 2). Natural peptides or proteins targeting
the brain can be endogenous, like hormones and apolipoproteins,
or exogenous, such as certain viruses and neurotoxins.33,69
Regarding phage display, although it has been extensively applied
for the last three decades,70 it has not been exploited to find BBB
shuttles until the last few years. Filamentous phages, which are
the most commonly used ones, measure 6.5 nm in diameter and
900 nm in length and are generally engineered to display only
5 copies of peptide per viral particle.71 These features, together
with the high number of sequences that can be displayed in
a phage library, explain why this screening technique has
provided peptides capable of transporting large cargoes such
as nanoparticles.
Ideally, BBB shuttles should target receptors with the follow-
ing attributes: high expression in the luminal side of brain
vasculature with respect to other tissues; capacity to mediate
transcytosis; high turnover and broad substrate recognition.72
Moreover, the physiological role of the transporter should
not be easily altered. Unfortunately, quantitative physiological
information of the wide variety of brain endothelium receptors
reported is very limited, thus screening together with trial and
error rather than design has mainly driven the discovery of new
shuttle peptides. Of note, although many sequences have been
reported to target a particular receptor, the contribution of
other mechanisms cannot be excluded.15 Determining whether
the molecule has reached the brain parenchyma is already a
challenge and studying the delivery route requires a multifocal
and integrated approach (Table 2).
The receptors with high expression on the BBB for which
transcytosis has been best characterized include: transferrin
(TfR1),40 low-density lipoproteins (LDLRs),73 insulin74 and leptin.75
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However, while the first two have been widely used for brain
delivery, very few BBB shuttle peptides derive from the others.76,77
LDLRs have been extensively studied for their roles in trans-
port and signalling78 and they are the most exploited receptors
for delivery across the BBB using peptides. Moreover, some of
them (particularly LRP1) are overexpressed in the brain79 and in
tumours.80 Peptides targeting this family of receptors either
are based on natural protein ligands, namely ApoB and ApoE
fragments81,82 and Angiopep-2, or they are found by phage
display biopanning against LDLR, like Peptide-22.27
TfR1 is also well characterized among BBB transport receptors.
Furthermore, it has even higher expression than LRP1 on the brain
endothelium83–85 and is widely present in tumours.86 Peptides
interacting with TfR1 were discovered by applying phage display
biopanning in various ways. B6 was identified in a nonamer library
screened against the extracellular domain of human TfR,87
whereas THR and T7 were found through panning against a
human receptor expressed in chicken fibroblasts (chicken TfR
does not bind human Tf),88 and the CRT peptide was found to
selectively target mouse brain parenchyma in vivo.89
In addition to the aforementioned receptors, many other
pathways have been explored in an attempt to increase brain
delivery eﬃciency and selectivity. The widespread occurrence of
some ion channels in the CNS, as well as their intracellular
traﬃc and recycling ability, have inspired several shuttles,
comprising RVG29, RDPs,90,91 KC2S,92 LCDX,93 DCDX,94
apamin,95,96 and MiniAp-4.97 By contrast, the endogenous peptide
GSH was identified as a BBB shuttle following from its reported
capacity to reach the brain through a saturable and specific
mechanism. Many transporters, some of which are preferentially
expressed in the CNS,98 mediate the influx and eﬄux of GSH
and its endogenous conjugates;99 however, further research is
required to elucidate the putative transcytotic mechanism of
GSH. Another shuttle derived from an endogenous peptide
is g7,100 which is discussed later in this review.
Although integrin receptors do not display a particularly high
expression in the brain microvasculature, they have been exten-
sively used for targeting brain tumours and inflamed regions of
the CNS.101 Cyclic RGD (cRGD)102 is a peptide derived from a
sequence present in many proteins that recognise these receptors.
Because integrin avb3 is overexpressed in the neovasculature,
cRGD has been extensively used to target nanoparticles into
gliomas.103 However, it can mediate transcytosis only indirectly
through internalization into leukocytes and other immune cells,
which are recruited into the brain in response to inflammation.19
Protein transporters are not the sole means to achieve a
certain degree of selectivity in the transcytosis across brain
endothelium. Gangliosides have a heterogeneous tissue distribu-
tion and can also mediate transport across polarized cells.104,105
This particular selective AMT mechanism has been exploited by
G23 peptide, which was found by phage display biopanning
against gangliosides GT1b
106 and GM1,107 the latter of which is
present in caveolae. G23 has been shown to promote the trans-
port of nanoparticles across the BBB107 and provide a targeting
eﬀect.108
Finally, several peptide shuttles have been found through
in vivo phage display biopanning without aiming for a parti-
cular receptor. The most prominent example is that of TGN.109
This sequence is actively transported across brain endothelial
cells and its brain selectivity suggests that the mechanism is
receptor-mediated. The brain delivery capacity of this shuttle is
supported by enhanced therapeutic eﬀect in glioblastoma and
Alzheimer’s mouse models.110,111
4. On the way to clinical application
The first generation of BBB shuttle peptides has reached clinical
trials in the last few years. Here we will describe the two best-
documented examples, Angiopep-2 and GSH. However, others are
Fig. 2 Sources of BBB shuttle peptides. (a) Phage display biopanning may be performed on isolated receptors, cells overexpressing a particular receptor
or in vivo. The phages that bind the receptors or accumulate in the brain are recovered, amplified through bacterial infection, titrated and sequenced. The
biopanning cycle is generally repeated 2–3 times and the most abundant sequences are chemically synthesized for further study. (b) For peptides coming
from (neurotropic) proteins, the moiety responsible for transport is identified through one or more of the following techniques: sequence alignment,
screening of synthesized fragments or structural studies involving X-ray and NMR. Here we highlight a sequence of ApoE (PDB: 1LPE) that has been
shown to interact with LRP1 (PDB: 2KNY).187 (c) Passive diffusion shuttles have been designed taking into account the parameters involved in this
permeation mechanism. The structure of phenylproline is presented here as the BBB peptide shuttle with the highest solubility and transport capacity.
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in advanced pre-clinical stages, and MTfp,112 a dodecapeptide
derived from melanotransferrin, has been announced to be
ready to enter clinical development.
4.1. Angiopep-2: an example of versatility
Angiopep-2 was identified by sequence alignment of aprotinin
with other human proteins having a Kunitz domain, which
interacts with LRP1 (Fig. 3).54,113 This BBB shuttle was initially
exploited to transport small molecules such as doxorubicin,114
etoposide,114 paclitaxel,115 and also peptides.116 Its conjugate with
paclitaxel (ANG1005 or GRN1005)117,118 showed good tolerance
in Phase I clinical studies119,120 and reached Phase II for the
treatment of recurrent high-grade glioma in combination with
bevacizumab (ClinicalTrials.gov identifier: NCT01480583).
ANG1005 is currently also in Phase II clinical trials for breast
cancer (ClinicalTrials.gov identifier: NCT02048059), and preli-
minary results show that this compound reduces tumours up to
60% in patients.121
Angiopep-2 has been used to transport a wide variety of
nanocarriers loaded with small molecules, proteins or genetic
material into the CNS. These carriers include liposomes,122,123
nanotubes,124 dendrimers made of polyamidoamine125–128
and poly-L-lysine,129 and also nanoparticles made of PEG–
polycaprolactam,130–133 PEG–poly(lactic-co-glycolate) (PEG–PLGA),134
thermoresponsive hydrogels,135 upconversion nanocrystals136
and gold.137 The diameter of these particles ranged from 7 to
200 nm thus further confirming the versatility of this shuttle.
Moreover, the number of peptides required for efficient delivery is
relatively low; four peptides are considered optimal for 7–8 nm
dendrons127 and 53 peptides on the surface of a 90 nm nanoparticle
provided efficient transport.25 The increase in brain delivery for
most constructs is in the range of 1.5- to 3-fold in mice.
The vast majority of studies with Angiopep-2 describe about
conjugates for the diagnosis125,136 or the treatment124,131,137 of
brain tumours; in the second case a significant increase in
survival with respect to the free drug or untargeted nanocarriers
has often been reported. Although this peptide has been used
mainly to transport small molecules and nanoparticles, conju-
gation of the shuttle to trastuzumab has recently been shown to
enhance the therapeutic eﬀect of this antibody in mice bearing
HER2+ brain tumours.138 Angiopep-2 also increases the anti-
fungal activity of amphotericin B in meningoencephalitis139,140
and the therapeutic index of phenytoin sodium against epilepsy in
rats.135 Additionally, delivery of Angiopep-2-coated nanoparticles
loaded with hGDNF boosts the neuroprotective eﬀect of this
protein in a Parkinsonian rat model, improving the locomotor
activity and recovery of dopaminergic neurons.129 Although in
some of these models, especially in those involving tumours, the
BBB may be compromised, permeation has also been assessed in
healthy mice and cell-based BBB models.135
4.2. GSH: a highly specialized shuttle
Together with Angiopep-2, GSH is the BBB shuttle peptide that
has reached most advanced stages in the route towards clinical
application. GSH has been mainly applied to target PEGylated
nanoliposomes loaded with drugs, which are thereby protected
from degradation and clearance. This formulation, known as
G-Technologys, has been applied to a wide range of compounds,
encompassing small molecules,141–143 peptides144 and, very
recently, biologics.145
G-Technologys for doxorubicin delivery (2B3-101) has
reached Phase I/IIa clinical trials for brain cancer treatment
(ClinicalTrials.gov identifier: NCT01386580). This nanoplatform
has also been exploited for the delivery of methylprednisolone
(2B3-201), enhancing its transport up to 6.5-fold.142 2B3-201 is
capable of reducing neuroinflammation in rats with encephalo-
myelitis, and reached Phase I clinical trials for multiple sclerosis55
(ClinicalTrials.gov identifier: NCT02048358). Even more remark-
able is the selective increase in brain delivery of single domain
antibodies against amyloid plaques in APP/PS1 mice.145
5. One shuttle, one cargo
The large change in physicochemical properties induced by thera-
peutic cargoes and the distinct location of the targets of these
drugs inside the brain has limited the universal aspiration of most
BBB shuttles. Hence, in general, each peptide shuttle is prominent
in the delivery of a particular family of cargoes. Although many
peptides have been reported for each type of cargo, here we will
focus on three well-documented case studies.
5.1. Gene delivery with RVG29
RVG29 was found when studying the neurotropism of the rabies
virus, which is mediated by its glycoprotein (RVG).53 Although a
tail with 9 arginines was introduced to bind siRNA, the unmodi-
fied peptide was shown to reach the brain parenchyma. This
observation suggested that the increase in brain delivery of the
oligoarginine-RVG29 construct was due to the targeting peptide
and not to the potential opening of tight junctions promoted
by the policationic sequence. This construct was first used to
transport oligonucleotides into healthy mouse brains to silence
GFP in GFP-transgenic mice as well as endogenous SOD1 in the
CNS. As a further demonstration of its value, this delivery strategy
was successfully applied to protect mice with JEV-induced
encephalitis. The authors reasoned that transport across the
BBB could take place by RMT through interaction with the a7
subunit of the nicotinic acetylcholine receptor (nAchR), as shown
by the selective binding of the peptide to neurons and its
competition with a-bungarotoxin. In a subsequent study,146
RVG29 was intravenously injected into mice and was found
inside cells that overexpress nAchR, unlike a scrambled version
of the sequence. Moreover, RVG29 was not detected when
administered to knockout animals devoid of this receptor.
The high potential of this sequence for gene delivery has been
confirmed using either the oligoarginine tail,147,148 a polylysine
dendrigraft,149 polyethylenimine,150,151 polyasparthydrazide151 or
polyamidoamide dendrimers152 to bind the oligonucleotide chains.
RVG29 linked to exosomes is particularly eﬃcient as it mediates
higher protein knockdown than when linked to oligoarginine
with five-fold less RNA.153 As an example of therapeutic eﬀect, the
polylysine dendrigraft targeted delivery of caspase-3 RNAi reduced
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caspase-3 levels, improving locomotor activity and rescuing dopami-
nergic neuronal loss in a rat model of Parkinson’s disease.154
5.2. Apolipoprotein-derived peptides for enzyme delivery
Apolipoproteins have been applied for brain delivery taking
advantage of their roles in lipid transport. Although the whole
proteins have been used to transport nanoparticles,155 the pep-
tides derived from them have mainly been applied to enzymes,
probably because of the lower eﬀect of the targeting moiety on
the enzymatic activity.
Apolipoprotein B100 (ApoB) is the primary component of
low-density lipoprotein and it interacts with LDLR and LRP2.79
Fig. 3 Angiopep-2 discovery and validation as a BBB shuttle. Angiopep-2 was discovered by alignment of Kunitz protein domains followed by a
screening of 96 analogues in a bovine cell-based blood–brain barrier model. The transport of the selected peptide was inhibited by low temperature,
RAP protein, and a2-macroglobulin, thereby indicating that the transcytosis was active and probably mediated by LRP-1.
113 However, several uptake
mechanisms may contribute to the transport of conjugates.25 This peptide has proven its efficiency as a BBB shuttle in vitro and in vivo. Whole-animal
fluorescence imaging and autoradiography among other techniques have shown that Angiopep-2 constructs accumulate in the brain. Additionally, there
is qualitative (e.g. microscopy. Image reproduced with permission from ref. 195. Copyright 2010 Elsevier) as well as quantitative (e.g. radioisotopic
labelling and capillary depletion) evidence proving that this peptide reaches the brain parenchyma. Angiopep-2 conjugated to paclitaxel is currently in
Phase II clinical trials.
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Spencer and Verma81 achieved hepatic expression of proteins
in the liver fused to the binding domain of ApoB (3371–3409,
P04114 UniProt), which resulted in sustained brain delivery. The
cDNA was introduced into the liver and spleen using a lentivirus
vector. Through this strategy, GFP and glucocerebrosidase were
delivered into the brain. Fluorescence microscopy revealed the
co-localization of thesemolecules in neurons and astrocytes in the
regions of the brain with a high expression of LDLR. Also using
ApoB (3371–3409) to target iduronate-2-sulphatase, the overall
brain pathology was improved in a mouse model of mucopoly-
saccharidosis type IIIA.156
Despite the successful cases of ApoB BBB shuttles, peptides
derived from ApoE showed higher eﬃciency when applied to
transport other proteins.82,157 This observation may be related
to ApoE binding a variety of LDLRs, including LRP1.79 Of note,
altering the homeostasis of this protein entails many secondary
eﬀects,9 which could be minimized using only the moiety
involved in transport. With the aim of finding the most suitable
fragment of ApoE, several sequences reported to interact with
LDLRs158,159 were compared.82 In this comprehensive study, ApoE
fragments were expressed as a fusion protein with a lysosomal
enzyme (IDUA) in the liver in order to target this enzyme to the
brain (Fig. 4).
One of the two peptides with the best performance found in
the aforementioned study82 was the tandem dimer sequence
ApoE (159–167)2 (UniProt P02649-1) which had better transport
in a cell-based BBB model than the monomer.160 This peptide
was also the best-ranked BBB shuttle in a very recent comparative
study157 using a mouse model for another lysosomal storage
disease, namelymetachromic leukodystrophy. In that publication,
ApoE (159–167)2 did not show the best performance in endo-
cytosis or in a porcine BBB cell-based model; however, it was the
only shuttle to increase the in vivo brain delivery of arylsulfatase A
(by 54%) when compared to Angiopep-2, ApoE (148–170), and
ApoB. Surprisingly, this shuttle did not compete with the endo-
genous protein as suggested by the lack of increased transport
efficiency in ApoE-knock out mice.
It is also worth highlighting the delivery of large proteins
into the brain using a physical mixture of the cargoes with ApoE
(151–170) in tandem with a 16-lysine sequence.161 However, this
construct has subsequently been found to prompt a transient
disruption of the BBB,162 as has been observed with other highly
positively charged carriers.163
5.3. g7-Mediated PLGA-nanoparticle delivery
Although Angiopep-2 has shown the highest versatility for nano-
particle delivery, many other shuttles have proven useful for
certain kinds of nanocarriers. In particular, the g7 heptapeptide
is a modified analogue of the synthetic opioid MMP-2200, in
which the N-terminal tyrosine was exchanged for phenylalanine
in order to avoid the antinociceptive eﬀect.100 It was also found
that O-glycosylation with glucose but not xylose or lactose
Fig. 4 Brain delivery of IDUA–ApoE (159–167)2 expressed in the liver. Increased delivery of IDUA into the mouse brain parenchyma was achieved by
expressing it as a fusion protein with ApoE (159–167)2 in mouse liver.
82 The fusion of ApoE peptide increased 3.6-fold the transport of IDUA in a pulse-
chase assay performed on a cell-based BBB model – in this experiment the protein is incubated and, after washing, the transport of the protein adsorbed
onto or internalized by endothelial cells is measured; this strategy intends to minimize the paracellular contribution to the transport, which is still a
concern in cell-based BBB models.21 Remarkably, the amount of IDUA found in the brain when expressed in mice livers fused to ApoE (159–167)2 was
20-fold higher than when expressed without the BBB shuttle. Quantification was performed after capillary-depletion. In addition, these authors provided
fluorescence microscopy images, which indicate colocalization of the construct with neurons and astrocytes and show a clear pattern of diffusion from
the capillary into the parenchyma. With this approach, 23% of normal brain IDUA activity was restored, which was sufficient to decrease brain
glycosaminoglycan and b-hexosaminidase concentrations to normal levels in mucopolysaccharidosis type I mice.
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favoured brain uptake. This observation, together with a remark-
able selectivity for this organ and a poor permeation of a scrambled
version of the peptide, indicates that transport across the BBB is
due to a receptor, though not necessarily opioid.
Numerous in vitro and in vivo studies show that g7 is capable
of delivering PEG–PLGA nanoparticles into the brain.164 The
increase in brain accumulation has been assessed by whole-animal
fluorescence imaging165 and also by measuring the amount of
rhodamine 123 released from the nanoparticle; remarkably, 15%
of the fluorophore administered intravenously was reported to
reach the brain. These nanoparticles are mainly delivered to the
grey matter166 and their presence in the brain parenchyma has
been imaged using fluorescence and transmission electron micro-
scopy. Further evidence of the therapeutic effect of this peptide-
coated nanocarriers upon intravenous injection would certainly
encourage a more widespread use.
6. Rescuing the origins
In general, CPPs and peptides undergoing passive diﬀusion
across the BBB do not provide brain selectivity. However, their
high internalizing capacity can be fine-tuned or exploited in
tandem with BBB shuttles in order to enhance the delivery of
cargoes to the brain.
6.1. Cell-penetrating peptides
TAT is the most used CPP for brain delivery for proteins52,167–170
and nanoparticles.171–173 However, in addition to its lack of brain
selectivity, very little qualitative or quantitative data are available
regarding intact BBB penetration. Although some studies achieve
a fast bulk brain accumulation and a few show an improved
therapeutic effect, others indicate that the constructs could be
trapped in brain endothelium. In this regard, one of the most
perspicuous examples is the 800-fold increase in ritonavir delivery
achieved two weeks after injection using TAT-coated polylactate
nanoparticles.174 As it could be expected from the cell-penetrating
ability of TAT, nanoparticles are efficiently internalized in brain
capillary endothelial cells, probably by adsorptive-mediated endo-
cytosis, and are slowly released as indicated by the parenchyma/
capillary ratio.
Nonetheless, recent studies have shown that dual-targeted
liposomes with either Angiopep-2–oligoarginine, T7–TAT, THR–
transportan or Tf combined with TAT, penetratin or mastoparan
outperformed those with a single targeting peptide, both in vitro
and in vivo.131,175–177 This strategy takes advantage of the pene-
trating capacity of CPPs by combining it with the higher selec-
tivity of receptor ligands. It would certainly be interesting to
study the effect of the double functionalization approach with
more novel, potent and less toxic CPPs such as dNP2.178
6.2. Passive diﬀusion shuttles
Passive diﬀusion BBB-shuttle peptides dramatically enhance the
transport of drugs like baicalin, dopamine, 4-aminobutanoic
acid, nipecotic acid and 5-aminolevulinic acid in a BBB cell-
based model and in the parallel artificial membrane permeability
assay (PAMPA),30–32 which is a well-established method to
measure passive diffusion.179 With the aim of further enhanc-
ing the transport capacity of prolyl oligopeptidase inhibitors,
diketopiperazines have been combined with a redox chemical
delivery system to avoid back transport across brain endo-
thelium.180 Very recently, the chirality of phenylproline shuttle
diastereomers has been shown to affect their permeability.68
Thus, the transport of these peptides may depend on the
phospholipid composition of biological membranes, thereby
suggesting a route towards cell-type and even tissue selectivity.
Furthermore, phenylprolines have overcome the low solubility
limitations of their forerunners.
Despite the achievements described above, the applicability
of BBB shuttle peptides that work through passive diﬀusion is
still limited by the lack of selectivity and the non-negligible
impact of the cargo on the eﬃciency of the shuttle and vice
versa. On the side of the BBB transport capacity, this problem
can be overcome by fine-tuning the peptide for each particular
cargo.29 In order to decrease the eﬀect of the construct on the
activity of the molecule, linkers that can be cleaved inside the
brain parenchyma could be incorporated.
7. Toward protease-resistant shuttles
Most of the sequences reported for the delivery of large cargoes
are linear and made of L-amino acid residues. Both of these
features make peptides susceptible to degradation by proteases,
a process that decreases their eﬃciency, especially in vivo.
Notwithstanding, many strategies can be applied to overcome
this limitation such as the use of non-natural amino acids,
N-methylation, and cyclization.50 Very recently, several publica-
tions have revealed the great potential of increasing the meta-
bolic resistance of BBB shuttle peptides.
7.1. The retro-enantio approach
The retro-enantio or retro-inverso sequence of a peptide is
obtained by changing the stereochemistry of all the amino acid
residues (from L- to D-amino acids) and reversing the order of
the sequence. In this way, the topochemical features and the
structure of the peptide are often preserved despite the inver-
sion of the amide bond, yielding highly protease-resistant
analogues. It has recently been shown that this approach
yields more eﬃcient BBB shuttles.94,181,182 In order to illustrate
this point, we will focus on the retro-enantio THR and DCDX
peptides.
THR is a dodecapeptide obtained by phage display that
interacts with TfR but does not compete with Tf.88 This peptide
shuttle enhances the in vitro and in vivo transport of gold NPs
coated with a peptide (LPFFD) capable of binding amyloid-b in
order to disrupt aggregates upon microwave irradiation.183
TEM micrographs confirmed the presence of NPs in the
parenchyma. Remarkably, it has recently been shown that the
retro-enantio version of THR (THRre) transports a variety of
cargoes with higher eﬃciency than the parent peptide in a cell-
based BBB model and in vivo.182 Moreover, THRre was capable
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of delivering quantum dots to the brain parenchyma as shown
by two-photon intravital microscopy (Fig. 5).
In contrast to THR, LCDX is a peptide of natural origin. This
linear fragment of snake neurotoxin candotoxin, which interacts
with nAchRs, was reported following the success of RVG29.93
LCDX increased nanoparticle accumulation in mouse brain and
enhanced the survival of tumour-bearing mice. Recently, the retro-
enantio analogue has been developed and shown to retain the
capacity to interact with the same receptor.94 Although the aﬃnity
of this analogue is 5-fold lower than the original peptide, its
transport capacity is enhanced because of its superior resistance
to proteases in serum and in the lysosome.
7.2. A venom-inspired peptidomimetic shuttle
The retro-enantio approach has proved highly eﬃcient. However,
this transformation decreases the aﬃnity for the transporter and
requires D-amino acids, thereby significantly raising production
costs. Hence, it would be of interest to identify alternative sources
of protease-resistant shuttles. Although the capacity of peptides
found in animal venoms has already been exploited in this field,
the relevance of preserving their knotted structure has been
overlooked.
Apamin is a bicyclic neurotoxin that binds KCa2.2 channels,
which are found in neural cells and the vasculature, and has
long been known to reach the CNS.184,185 This peptide is highly
Fig. 5 Protease-resistance provides eﬃcient BBB shuttle peptides. (a) Structural modifications to achieve protease-resistance that have been applied to
BBB shuttle peptides. (b) The half-life of THR peptide is 30 min, whereas that of the retro-enantio version (THRre) is over 24 h.182 As a result, THRre
transcytosed in a cell-based BBB model and accumulated in the brain more eﬃciently. Furthermore, this peptide was capable of delivering quantum dots
across the BBB as shown by intracranial two-photon microscopy (bottom; capillaries are shown in green and quantum dots in red. The image is
reproduced with permission from ref. 182. Copyright 2015 Wiley); this technique avoids artefacts introduced during perfusion, necropsy and tissue
preparation for ex vivo microscopy imaging. (c) Cyclization of peptides also results in increased protease-resistance as illustrated in the case of apamin
derivatives.97 In addition, introducing non-natural elements such as substitution of a disulfide bond by a lactam bridge to produce peptidomimetics like
MiniAp-4 further reinforces metabolic stability. MiniAp-4 enhanced the transport of a variety of cargoes in mice and in a human cell-based BBB model.
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resistant to proteases95 and is capable of targeting nanoparticles
and proteins to the brain.96 However, high toxicity and immuno-
genicity, as well as a relatively complex structure, have discouraged
its extended application as a shuttle. Recently, MiniAp-4, which is a
safer and minimized version of apamin cyclized through a lactam
bridge, has been reported.97 Importantly, this cyclic peptidomi-
metic preserves the high protease-resistance and brain targeting
ability of apamin and has reduced toxicity and immunogenicity.
MiniAp-4 is more permeable than the natural peptide and can
transport nanoparticles and proteins in a human cell-based model
of the BBB. Furthermore, this shuttle can carry a cargo across the
BBB in mice and displays remarkable selectivity for the brain.
8. Conclusions and outlook
Although the BBB remains a formidable obstacle, since the
Trojan horse concept was coined in the 1980s, the field of drug
delivery to the brain has made remarkable progress. In the last
few years, a plethora of new BBB shuttle peptides have emerged
and hold great promise to overcome the limitations of the first
generation of shuttles dominated by large proteins. Peptides
are more aﬀordable, easier to characterize and to link to nano-
carriers or proteins. Moreover, they have lower immunogenicity
and often have a reduced eﬀect on the activity of the cargo than
their larger counterparts. Furthermore, many peptide shuttles do
not compete with endogenous substrates in contrast to endo-
genous proteins, nor stay bound to the receptor unlike some
antibodies. BBB shuttle peptides have so far provided promising
results in terms of brain delivery in preclinical settings. In addi-
tion, a relevant increase in the therapeutic eﬀect has been proven
in a wide variety of animal disease models, with a focus on brain
tumours but also including neurodegenerative and lysosomal
diseases as well as epilepsy among others.
Despite the considerable achievements described, new shuttles
with higher transport capacity and selectivity are required.
Approaches like phage display and natural sources of peptides that
reach the CNS oﬀer an excellent opportunity to explore the multi-
tude of poorly characterized or still unknown routes into the brain.
These strategies should be complemented with additional eﬀorts
in the characterization of the transport mechanisms and in global
proteomic approaches to identify new receptors. Also, further com-
parative studies between shuttles and a more accurate quantifica-
tion of the free drug in the brain parenchyma would enable a more
eﬃcient identification and optimization of BBB shuttles. The
next generation of BBB shuttle peptides should aim for an
enhanced metabolic stability, a higher transendothelial transport
and an improved selectivity for the brain – even for particular
regions of this organ – possibly through yet uncharacterized
transctytotic pathways.
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